The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Vasenina E.E.

Russian Medical Academy of Continuous Professional Education

Levin O.S.

Russian Medical Academy of Continuous Professional Education

Speech disorders in neurodegenerative diseases as dysphasia manifestation

Authors:

Vasenina E.E., Levin O.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(5): 50‑59

DOI: 10.17116/jnevro202012005150

Read: 8395 times

Contact the author
Table of contents

SPEECH DISORDERS IN NEURODEGENERATIVE DISEASES AS DYSPHASIA MANIFESTATION
SPEECH DISORDERS IN NEURODEGENERATIVE DISEASES AS DYSPHASIA MANIFESTATION

To cite this article:

Vasenina EE, Levin OS. Speech disorders in neurodegenerative diseases as dysphasia manifestation. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(5):50‑59. (In Russ.)
https://doi.org/10.17116/jnevro202012005150

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The Duchenne muscular dystrophy continuum: a modi­fied staging classification. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):60-70
Review of the diagnostic tools for speech diso­rders in Russian-speaking children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):63-68
Frequency of nutritional defi­ciency in patients with Alzheimer’s disease and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):113-119
Gerstmann—Sträussler—Scheinker disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(4):143-149
Comparative morphometric analysis of the sizes of the body and branch of the mandible in adolescents with various forms of unde­rdevelopment of the mandible: deve­lopment of a classification of the degrees of unde­rdevelopment and an algo­rithm for choosing surgical tactics. Stomatology. 2025;(6-2):65-72
Extramammary Paget’s disease. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(6):726-733
Classification of digi­tal medi­cal products and services. Medi­cal Technologies. Asse­ssment and Choice. 2026;(1):11-25
Abstract:

OBJECTIVE

To develop the classification and methodology for assessment of speech disorders in neurodegenerative diseases, and to identify the characteristics of speech disorders for various forms.

MATERIALS AND METHODS

The study included 1016 patients with neurodegenerative diseases. Screening assessment identified 42.1% patients with speech disorders exceeding isolated dysarthria. Patients were assessed using the speech disorder test battery developed by the authors. Cluster, multifactor and contingency analyses were performed.

RESULTS

Nine subtypes of speech disorders were identified in neurodegenerative diseases that we denominated as dysphasia. Based on contingency analysis, the principal and the additional dysphasia variants were identified for each form of neurodegenerative pathology, which may contribute to better understanding of various phenotypes. Based on the general scheme of speech origination, the level of disorders typical for a given dysphasia subtype was identified.

CONCLUSION

The proposed classification enables identification of the subtypes of speech disorders for individual forms of neurodegenerative diseases. Introducing dysphasia concept to clinical practice will improve differential diagnosis and understanding of phenotypical heterogeneity of each nosological form as well as will facilitate therapy optimization.

Keywords:

neurodegenerative diseases
dysphasia
speech disorder
classification

Authors:

Vasenina E.E.

Russian Medical Academy of Continuous Professional Education

Levin O.S.

Russian Medical Academy of Continuous Professional Education

Received:

06.03.2020

Accepted:

10.03.2020

Close metadata

References:

  1. Vasenina EE, Levin OS, Sonin AG. Modern trends in epidemiology of dementia and management of patients with cognitive impairment. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;117(6):87-95. (In Russ.). https://doi.org/10.17116/jnevro20171176287-95
  2. Rosinskaya AV, Vasenina EE, Khaybullin TN, Levin OS. Rate of progression of Parkinson’s disease with early and delayed prescription of levodopa preparations. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;118(6):77-81. (In Russ.). https://doi.org/10.17116/jnevro201811806277
  3. Irwin DJ, Lee VM, Trojanowski JQ. Parkinson’s disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci. 2013;14(9):626-636.  https://doi.org/10.1038/nrn3549
  4. Chung EJ, Babulal GM, Monsell SE, Cairns NJ, Roe CM, Morris JC. Clinical Features of Alzheimer Disease With and Without Lewy Bodies. JAMA Neurol. 2015;72(7):789-796.  https://doi.org/10.1001/jamaneurol.2015.0606
  5. Lebouvier T, Pasquier F, Buée L. Update on tauopathies. Curr Opin Neurol. 2017;30(6):589-598.  https://doi.org/10.1097/WCO.0000000000000502
  6. Teichmann M, Ferrieux S. Aphasia(s) in Alzheimer. Rev Neurol (Paris). 2013;169(10):680-686.  https://doi.org/10.1016/j.neurol.2013.06.001
  7. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. https://doi.org/10.1212/WNL.0b013e31821103e6
  8. Caselli RJ, Beach TG, Sue LI, Connor DJ, Sabbagh MN. Progressive aphasia with Lewy bodies. Dement Geriatr Cogn Disord. 2002;14(2):55-58.  https://doi.org/10.1159/000064925
  9. Baumann A, Nebel A, Granert O, Giehl K, Wolff S, Schmidt W, Baasch C, Schmidt G, Witt K, Deuschl G, Hartwigsen G, Zeuner KE1, van Eimeren T. Neural Correlates of Hypokinetic Dysarthria and Mechanisms of Effective Voice Treatment in Parkinson Disease. Neurorehabil Neural Repair. 2018;32(12):1055-1066. https://doi.org/10.1177/1545968318812726
  10. Rusz J, Tykalová T, Salerno G, Bancone S, Scarpelli J, Pellecchia MT. Distinctive speech signature in cerebellar and parkinsonian subtypes of multiple system atrophy. J Neurol. 2019;266(6):1394-1404. https://doi.org/10.1007/s00415-019-09271-7
  11. Hernandez I, Fernandez MV, Tarraga L, Boada M, Ruiz A. Frontotemporal Lobar Degeneration (FTLD): Review and Update for Clinical Neurologists. Curr Alzheimer Res. 2018;15(6):511-530.  https://doi.org/10.2174/1567205014666170725130819
  12. Utianski RL, Duffy JR, Clark HM, Strand EA, Botha H, Schwarz CG, Machulda MM Senjem ML, Spychalla AJ, Jack CR Jr, Petersen RC, Lowe VJ, Whitwell JL, Josephs KA. Prosodic and phonetic subtypes of primary progressive apraxia of speech. Brain Lang. 2018;184:54-65.  https://doi.org/10.1016/j.bandl.2018.06.004
  13. Luria AR. Aphasia reconsidered. Cortex. 1972;8(1):34-40.  https://doi.org/10.1016/s0010-9452(72)80025-x
  14. Fridriksson J, den Ouden DB, Hillis AE, Hickok G, Rorden C, Basilakos A, Yourganov G, Bonilha L. Anatomy of aphasia revisited. Brain. 2018;141(3):848-862.  https://doi.org/10.1093/brain/awx363
  15. Levelt WJM. How Speech Evolved: Some Historical Remarks. J Speech Lang Hear Res. 2019;62(8):2926-2931. https://doi.org/10.1044/2019_JSLHR-S-CSMC7-19-0017
  16. Glozman JM. A brief history of Russian aphasiology. Neuropsychol Rev. 1996;6(1):1-10.  https://doi.org/10.1007/bf01875417
  17. Leont’ev AA. Vygotsky’s school: the line of continuity. Psihologicheskii zhurnal. 2014;25(5):98-103. (In Russ.).
  18. Giannini LA, Irwin DJ, McMillan CT, Ash S, Rascovsky K, Wolk DA, Van Deerlin VM, Lee EB, Trojanowski JQ, Grossman M. Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia. Neurology. 2017;88(24):2276-2284. https://doi.org/10.1212/WNL.0000000000004034
  19. Leyton CE, Hodges JR, McLean CA, Kril JJ, Piguet O, Ballard KJ. Is the logopenic-variant of primary progressive aphasia a unitary disorder? Cortex. 2015;67:122-133.  https://doi.org/10.1016/j.cortex.2015.03.011
  20. Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017;32(6):853-864.  https://doi.org/10.1002/mds.26987
  21. Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, Van Deerlin VM, Lee VM, Trojanowski JQ. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol. 2015;129(4):469-491.  https://doi.org/10.1007/s00401-014-1380-1
  22. Arefyeva AP, Skripkina NA, Vasenina EE. Speech disorders in Parkinson’s disease. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2019;119(9):32-36. (In Russ.). https://doi.org/10.17116/jnevro201911909232
  23. Buoli M, Serati M, Caldiroli A, Galimberti D, Scarpini E, Altamura AC. Pharmacological Management of Psychiatric Symptoms in Frontotemporal Dementia: A Systematic Review. J Geriatr Psychiatry Neurol. 2017;30(3):162-169.  https://doi.org/10.1177/0891988717700506
  24. Logroscino G, Imbimbo BP, Lozupone M, Sardone R, Capozzo R, Battista P, Zecca C, Dibello V, Giannelli G, Bellomo A, Greco A, Daniele A, Seripa D, Panza F. Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs. Expert Opin Pharmacother. 2019;20(9):1091-1107. https://doi.org/10.1080/14656566.2019.1598377
  25. Kishi T, Matsunaga S, Oya K, Nomura I, Ikuta T, Iwata N. Memantine for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis. J Alzheimers Dis. 2017;60(2):401-425.  https://doi.org/10.3233/JAD-170424
  26. Meng YH, Wang PP, Song YX, Wang JH. Cholinesterase inhibitors and memantine for Parkinson’s disease dementia and Lewy body dementia: A meta-analysis. Exp Ther Med. 2019;17(3):1611-1624. https://doi.org/10.3892/etm.2018.7129
  27. Kishi T, Matsunaga S, Iwata N. Memantine for the treatment of frontotemporal dementia: a meta-analysis. Neuropsychiatr Dis Treat. 2015;11:2883-2885. Published 2015 Nov 12.  https://doi.org/10.2147/NDT.S94430
  28. Ferris S, Ihl R, Robert P, Winblad B, Gatz G, Tennigkeit F, Gauthier S. Treatment effects of Memantine on language in moderate to severe Alzheimer’s disease patients. Alzheimers Dement. 2009;5(5):369-374.  https://doi.org/10.1016/j.jalz.2009.05.604
  29. Johnson NA, Rademaker A, Weintraub S, Gitelman D, Wienecke C, Mesulam M. Pilot trial of memantine in primary progressive aphasia. Alzheimer Dis Assoc Disord. 2010;24(3):308.  https://doi.org/10.1097/WAD.0b013e3181cf468d
  30. Boxer AL, Lipton AM, Womack K, Merrilees J, Neuhaus J, Pavlic D, Gandhi A, Red D, Martin-Cook K, Svetlik D, Miller BL. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2009;23(3):211-217.  https://doi.org/10.1097/WAD.0b013e318197852f
  31. Chow TW, Fam D, Graff-Guerrero A, Verhoeff NP, Tang-Wai DF, Masellis M, Black SE, Wilson AA, Houle S, Pollock BG. Fluorodeoxyglucose positron emission tomography in semantic dementia after 6 months of memantine: an open-label pilot study. Int J Geriatr Psychiatry. 2013;28(3):319-325.  https://doi.org/10.1002/gps.3832
  32. Barbancho MA, Berthier ML, Navas-Sánchez P, Dávila G, Green-Heredia C, García-Alberca, Ruiz-Cruces R, López-González MV, Dawid-Milner MS, Pulvermüller F, Lara JP. Bilateral brain reorganization with memantine and constraint-induced aphasia therapy in chronic post-stroke aphasia: An ERP study. Brain Lang. 2015;145-146:1-10.  https://doi.org/10.1016/j.bandl.2015.04.003
  33. Berthier ML, Green C, Lara JP, Higueras C, Barbancho MA, Dávila G, Pulvermüller F. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. Ann Neurol. 2009;65(5):577-585.  https://doi.org/10.1002/ana.21597
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.